Charles M Gallagher, Spencer K Yingling, Aaron Cumpston, Lauren Veltri, Salah Ud Din Safi, Sijin Wen, Kelsea Seago
{"title":"Evaluation of Titer-Proven Response Rates of Pediatric Hepatitis B-Combination Vaccines in Adult Hematopoietic Cell Transplant Recipients.","authors":"Charles M Gallagher, Spencer K Yingling, Aaron Cumpston, Lauren Veltri, Salah Ud Din Safi, Sijin Wen, Kelsea Seago","doi":"10.1111/tid.70005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients who have undergone hematopoietic cell transplant (HCT) should be revaccinated with common childhood vaccines due to loss of immunity. It is common for transplant centers to encourage adherence by administering combination vaccines to alleviate high vaccine burden. A combination product containing pediatric doses of hepatitis B surface antigen (10 µg) is commonly utilized, although limited data are available on response post-HCT.</p><p><strong>Methods: </strong>The primary objective of this study was to determine the efficacy of a low-dose, combination hepatitis B vaccine by assessing titer-proven response rates. The secondary objective was to characterize factors that influence non-response. Post-HCT patients were included in this analysis if they received all three post-HCT doses of low-dose DTaP-HepB-IPV with a subsequently documented hepatitis B titer result. Following the successful completion of the protocol, patients were considered responders to the vaccine if they had measurable titers ≥10 mIU/mL.</p><p><strong>Results: </strong>Thirty-nine patients met inclusion criteria. A serologic response to the vaccine series was observed in 21 of the 39 patients (54%). Allogeneic HCT recipients were found to have a response rate of 76%, whereas autologous recipients were less likely to respond (response rate 36%, p = 0.02).</p><p><strong>Conclusion: </strong>An appropriate response to a low-dose, combination hepatitis B vaccine was observed in allogeneic HCT recipients. Autologous response rates are low, though this finding is consistent with prior literature.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70005"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplant Infectious Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/tid.70005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Patients who have undergone hematopoietic cell transplant (HCT) should be revaccinated with common childhood vaccines due to loss of immunity. It is common for transplant centers to encourage adherence by administering combination vaccines to alleviate high vaccine burden. A combination product containing pediatric doses of hepatitis B surface antigen (10 µg) is commonly utilized, although limited data are available on response post-HCT.
Methods: The primary objective of this study was to determine the efficacy of a low-dose, combination hepatitis B vaccine by assessing titer-proven response rates. The secondary objective was to characterize factors that influence non-response. Post-HCT patients were included in this analysis if they received all three post-HCT doses of low-dose DTaP-HepB-IPV with a subsequently documented hepatitis B titer result. Following the successful completion of the protocol, patients were considered responders to the vaccine if they had measurable titers ≥10 mIU/mL.
Results: Thirty-nine patients met inclusion criteria. A serologic response to the vaccine series was observed in 21 of the 39 patients (54%). Allogeneic HCT recipients were found to have a response rate of 76%, whereas autologous recipients were less likely to respond (response rate 36%, p = 0.02).
Conclusion: An appropriate response to a low-dose, combination hepatitis B vaccine was observed in allogeneic HCT recipients. Autologous response rates are low, though this finding is consistent with prior literature.
期刊介绍：
Transplant Infectious Disease has been established as a forum for presenting the most current information on the prevention and treatment of infection complicating organ and bone marrow transplantation. The point of view of the journal is that infection and allograft rejection (or graft-versus-host disease) are closely intertwined, and that advances in one area will have immediate consequences on the other. The interaction of the transplant recipient with potential microbial invaders, the impact of immunosuppressive strategies on this interaction, and the effects of cytokines, growth factors, and chemokines liberated during the course of infections, rejection, or graft-versus-host disease are central to the interests and mission of this journal.
Transplant Infectious Disease is aimed at disseminating the latest information relevant to the infectious disease complications of transplantation to clinicians and scientists involved in bone marrow, kidney, liver, heart, lung, intestinal, and pancreatic transplantation. The infectious disease consequences and concerns regarding innovative transplant strategies, from novel immunosuppressive agents to xenotransplantation, are very much a concern of this journal. In addition, this journal feels a particular responsibility to inform primary care practitioners in the community, who increasingly are sharing the responsibility for the care of these patients, of the special considerations regarding the prevention and treatment of infection in transplant recipients. As exemplified by the international editorial board, articles are sought throughout the world that address both general issues and those of a more restricted geographic import.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
